603 related articles for article (PubMed ID: 14988748)
1. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
2. Death receptor ligands, in particular TRAIL, to overcome drug resistance.
de Jong S; Timmer T; Heijenbrok FJ; de Vries EG
Cancer Metastasis Rev; 2001; 20(1-2):51-6. PubMed ID: 11831647
[TBL] [Abstract][Full Text] [Related]
3. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
Kajiwara K; Saito A; Ogata S; Tanihara M
Biochim Biophys Acta; 2004 Jun; 1699(1-2):131-7. PubMed ID: 15158720
[TBL] [Abstract][Full Text] [Related]
4. The potential of TRAIL for cancer chemotherapy.
Nagane M; Huang HJ; Cavenee WK
Apoptosis; 2001 Jun; 6(3):191-7. PubMed ID: 11388668
[TBL] [Abstract][Full Text] [Related]
5. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
6. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
7. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.
Reesink-Peters N; Hougardy BM; van den Heuvel FA; Ten Hoor KA; Hollema H; Boezen HM; de Vries EG; de Jong S; van der Zee AG
Gynecol Oncol; 2005 Mar; 96(3):705-13. PubMed ID: 15721415
[TBL] [Abstract][Full Text] [Related]
8. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
9. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway.
Shin EC; Ahn JM; Kim CH; Choi Y; Ahn YS; Kim H; Kim SJ; Park JH
Int J Cancer; 2001 Jul; 93(2):262-8. PubMed ID: 11410875
[TBL] [Abstract][Full Text] [Related]
11. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
12. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
13. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway.
Liu B; Fan Z
Oncogene; 2001 Jun; 20(28):3726-34. PubMed ID: 11439335
[TBL] [Abstract][Full Text] [Related]
14. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer.
Mitsiades CS; Poulaki V; Mitsiades N
J Endocrinol; 2003 Aug; 178(2):205-16. PubMed ID: 12904168
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
16. Steering anti-cancer drugs away from the TRAIL.
Nagata S
Nat Med; 2000 May; 6(5):502-3. PubMed ID: 10802698
[No Abstract] [Full Text] [Related]
17. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
Poulaki V; Mitsiades CS; McMullan C; Fanourakis G; Negri J; Goudopoulou A; Halikias IX; Voutsinas G; Tseleni-Balafouta S; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):358-66. PubMed ID: 15623796
[TBL] [Abstract][Full Text] [Related]
18. Targeting death receptors to fight cancer: from biological rational to clinical implementation.
Mocellin S
Curr Med Chem; 2010; 17(25):2713-28. PubMed ID: 20586721
[TBL] [Abstract][Full Text] [Related]
19. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
20. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells.
Delmas D; Rébé C; Micheau O; Athias A; Gambert P; Grazide S; Laurent G; Latruffe N; Solary E
Oncogene; 2004 Nov; 23(55):8979-86. PubMed ID: 15480430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
